A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Summary

This is a platform study evaluating the safety and efficacy of multiple novel investigational products (IPs) that target unresectable or metastatic cutaneous melanoma in participants who have failed standard treatment.

Timeline

Start

2022-11-01

Primary completion

2027-06-30

Completion

2027-12-31

Outcome

Outcome not reported

Stopped (Business): “Sponsor Strategy”

Drugs

Indications